House
Sign inCreate account
Drug lookup
Drug reference

tisagenlecleucel

CAR T cell therapy (CD19-targeted) · anticancer, cellular therapy

CAR T cell therapy (CD19-targeted)anticancer, cellular therapy
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
  • AdalimumabSevereDatabaseDDInter
  • BaricitinibSevereDatabaseDDInter
  • CertolizumabSevereDatabaseDDInter
  • CladribineSevereDatabaseDDInter

Mechanism

Tisagenlecleucel is a CD19 CAR-expressing autologous T cell–based immunotherapy. The CAR is composed of a murine single-chain antibody fragment that recognizes CD19 and is fused to intracellular signaling domains from 4-1BB (CD137) and CD3 zeta. CD3 zeta is critical for initiating T-cell activation and antitumor activity, while 4-1BB enhances cell expansion and survival.

Indications

ALL that is refractory or in second or later relapse

Side effects

Serious
  • cytokine release syndrome (fever, nausea, headache, rapid heartbeat, low blood pressure, and dyspnea)
  • neurological toxicities

Drug interactions

Adalimumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Baricitinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Certolizumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Cladribine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Clozapine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Deferiprone
Severe
Database

Clinical effect not specified

Source: DDInter

Etanercept
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Fingolimod
Severe
Database

Clinical effect not specified

Source: DDInter

Golimumab
Severe
Database

Clinical effect not specified

Source: DDInter

Infliximab
Severe
Database

Clinical effect not specified

Source: DDInter

Leflunomide
Severe
Database

Clinical effect not specified

Source: DDInter

Measles Virus Vaccine Live Attenuated
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Stroke and TIA — secondary prevention
AHA · Neurology · 2021
Dyslipidaemia management
ICMR · Cardiology · 2023
Rheumatoid arthritis
EULAR · Rheumatology · 2022
Glomerular diseases
KDIGO · Nephrology · 2021
Rheumatoid arthritis
ACR · Rheumatology · 2021

Ask House about tisagenlecleucel

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team